Ind-Swift Laboratories Limited (NSE:INDSWFTLAB)

Market Cap	8.95B
Revenue (ttm)	5.72B
Net Income (ttm)	2.34B
Shares Out	81.61M
EPS (ttm)	29.96
PE Ratio	3.66
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	289,867
Average Volume	316,896
Open	106.96
Previous Close	106.85
Day's Range	106.95 - 116.00
52-Week Range	68.72 - 124.00
Beta	0.42
RSI	66.77
Earnings Date	Feb 10, 2026

About Ind-Swift Laboratories

Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson’s disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticance...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 1,246
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: INDSWFTLAB

Financial Performance

In 2024, Ind-Swift Laboratories's revenue was 5.62 billion, a decrease of -67.13% compared to the previous year's 17.09 billion. Earnings were 2.50 billion, a decrease of -53.51%.